CN112105349A - A2-73结晶多晶型物质组合物及其使用方法 - Google Patents

A2-73结晶多晶型物质组合物及其使用方法 Download PDF

Info

Publication number
CN112105349A
CN112105349A CN201980031851.3A CN201980031851A CN112105349A CN 112105349 A CN112105349 A CN 112105349A CN 201980031851 A CN201980031851 A CN 201980031851A CN 112105349 A CN112105349 A CN 112105349A
Authority
CN
China
Prior art keywords
crystalline
formulation
salt
dosage form
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031851.3A
Other languages
English (en)
Chinese (zh)
Inventor
C·U·米斯林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of CN112105349A publication Critical patent/CN112105349A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
CN201980031851.3A 2018-04-12 2019-04-12 A2-73结晶多晶型物质组合物及其使用方法 Pending CN112105349A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656435P 2018-04-12 2018-04-12
US62/656,435 2018-04-12
PCT/US2019/027369 WO2019200345A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Publications (1)

Publication Number Publication Date
CN112105349A true CN112105349A (zh) 2020-12-18

Family

ID=68163817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031851.3A Pending CN112105349A (zh) 2018-04-12 2019-04-12 A2-73结晶多晶型物质组合物及其使用方法

Country Status (7)

Country Link
US (3) US11498908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773531A4 (cg-RX-API-DMAC7.html)
JP (4) JP7532718B2 (cg-RX-API-DMAC7.html)
CN (1) CN112105349A (cg-RX-API-DMAC7.html)
AU (2) AU2019253028B2 (cg-RX-API-DMAC7.html)
CA (2) CA3096671C (cg-RX-API-DMAC7.html)
WO (1) WO2019200345A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208133A1 (zh) * 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103108631A (zh) * 2010-06-15 2013-05-15 格吕伦塔尔有限公司 用于治疗疼痛的联合药物
WO2017013498A2 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
CN107708687A (zh) * 2015-07-22 2018-02-16 阿纳韦克斯生命科学公司 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体(ANAVEX2‑73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
GR1008233B (el) * 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103108631A (zh) * 2010-06-15 2013-05-15 格吕伦塔尔有限公司 用于治疗疼痛的联合药物
WO2017013498A2 (en) * 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions
CN107708687A (zh) * 2015-07-22 2018-02-16 阿纳韦克斯生命科学公司 四氢‑N,N‑二甲基‑2,2‑二苯基‑3‑呋喃甲胺的对映体(ANAVEX2‑73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023208133A1 (zh) * 2022-04-29 2023-11-02 苏州科睿思制药有限公司 布拉美森盐酸盐的晶型及其制备方法和用途

Also Published As

Publication number Publication date
JP2021521188A (ja) 2021-08-26
AU2024205423B2 (en) 2026-06-25
JP2025131907A (ja) 2025-09-09
US20230142424A1 (en) 2023-05-11
US11498908B2 (en) 2022-11-15
JP7532718B2 (ja) 2024-08-14
EP3773531A4 (en) 2021-06-23
AU2019253028A1 (en) 2020-10-15
CA3256071A1 (en) 2025-10-31
US12180174B2 (en) 2024-12-31
AU2019253028B2 (en) 2024-05-30
AU2024205423A1 (en) 2024-08-22
US20250115566A1 (en) 2025-04-10
JP2024038524A (ja) 2024-03-19
JP7758768B2 (ja) 2025-10-22
EP3773531A1 (en) 2021-02-17
US20210115004A1 (en) 2021-04-22
JP2026004574A (ja) 2026-01-14
CA3096671A1 (en) 2019-10-17
WO2019200345A1 (en) 2019-10-17
CA3096671C (en) 2025-09-16

Similar Documents

Publication Publication Date Title
JP7758768B2 (ja) 物質のa2-73結晶多形組成物およびそれらの使用方法
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
CN103945848A (zh) 被取代的喹唑啉酮的口服即释制剂
EP3294719A1 (en) Vortioxetine pyroglutamate
ES2727577T5 (en) Pharmaceutical composition containing an anti-nucleating agent
BR112019010816A2 (pt) composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composição farmacêutica, compostos, composto de fórmula viii, composto de fórmula ix, e composto de fórmula x
DK2961391T3 (en) Formulation comprising a benzothiazolone compound
US10919906B2 (en) Conformationally-constrained bioisosteres of caffeic acid, and synthesis and therapeutic uses
CN118019541A (zh) 在酸性pH下具有增强的效力的N-甲基-D-天冬氨酸受体的GLUN2B-亚基选择性拮抗剂
WO2012023145A2 (en) Prasugrel hydrochloride crystalline particles
WO2016114727A1 (en) Cefditoren pivoxil compositions with improved stability and production methods thereof
CN105017281A (zh) 一类安妥沙星的盐及其制备方法和用途
JP7828354B2 (ja) 中枢神経系への低疎水性の生物活性薬に対して化学的にカップリングされたトランスポーター
CN119997948A (zh) 用于预防退行性疾病引起的认知下降的组合物和方法
HK40045152B (en) Crystalline epinephrine malonate salt
HK1206736B (en) Seca inhibitors and methods of making and using thereof
HK1212213B (en) Formulation comprising benzothiazolone compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: C. U. mishlin

Inventor after: A. Selvi

Inventor before: C. U. mishlin